Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma (AIM-HN)
NCT03719690Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of tipifarnib in head and neck squamous cell carcinoma (HNSCC), sponsored by Kura Oncology. Started Mar 2019; status: completed.
02
Drugs
tipifarnib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03719690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719690.